本季度信息
截至2025年9月30日止六个月，中国卫生集团实现营收约1,961万港元，同比上期约1,868万港元增长约5%。毛利约185万港元，相比上期约199万港元略有下降，毛利率从上期的约10.7%下降至约9.4%。经调整后净亏损约1,036万港元，相比上期的约1,739万港元有所收窄。经营活动产生的净现金流约240万港元，而上期为负值，显示经营现金流同比大幅改善。期间销售及行政费用率也得到一定优化，其中销售及分销开支下降至约188万港元，行政开支降低至约1,090万港元。
业务分项
在医疗器械及耗材分销及服务方面，实现营收约1,560万港元，同比增长约18%。该板块主要向医院和诊所供应多种手术耗材以及提供相关服务，虽然营收增幅明显，但受定价与竞争因素影响，该板块仍录得约130万港元的Segment层面亏损。
在医院经营及管理服务方面，实现营收约410万港元，较上期约550万港元有所下滑，主要原因在于二级医院外科手术数量减少、门诊量与诊疗费单价下调等因素影响。该板块亏损约330万港元，与上期基本持平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.